Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cimzia 200mg/1ml solution for injection pre-filled pens
1001030Y0BBABAB
|
Cimzia | Certolizumab pegol | Musculoskeletal and Joint Diseases | No data available |
|
Cinaziere 15mg tablets
0406000D0BDAAAA
|
Cinaziere | Cinnarizine | Central Nervous System | No data available |
|
Cinchocaine 1.1% ointment
0107010G0AAAAAA
|
Cinchocaine hydrochloride | Cinchocaine hydrochloride | Gastro-Intestinal System | No data available |
|
Cinnarizine 10mg/5ml oral suspension
0406000D0AAACAC
|
Cinnarizine (Nausea & Vertigo) | Cinnarizine | Central Nervous System | No data available |
|
Cinnarizine 15mg/5ml oral suspension
0406000D0AAADAD
|
Cinnarizine (Nausea & Vertigo) | Cinnarizine | Central Nervous System | No data available |
|
Cinnarizine 75mg capsules
0206040AAAAAAAA
|
Cinnarizine (Peripheral Vasodilator) | Cinnarizine | Cardiovascular System | No data available |
|
Cinqaero 100mg/10ml concentrate for inf vials
0304020Z0BBAAAA
|
Cinqaero | Reslizumab | Respiratory System | No data available |
|
Cinqaero 25mg/2.5ml concentrate for inf vials
0304020Z0BBABAB
|
Cinqaero | Reslizumab | Respiratory System | No data available |
|
Cinryze 500unit inj vials
0304030F0BFAAAA
|
Cinryze | C1-Esterase inhibitor | Respiratory System | No data available |
|
Cipralex 10mg/ml oral drops
0403030X0BBADAD
|
Cipralex | Escitalopram | Central Nervous System | No data available |
|
Cipramil 10mg tablets
0403030D0BBABAB
|
Cipramil hydrobromide | Citalopram hydrobromide | Central Nervous System | No data available |
|
Cipramil 40mg tablets
0403030D0BBACAC
|
Cipramil hydrobromide | Citalopram hydrobromide | Central Nervous System | No data available |
|
Ciprofloxacin 100mg/50ml solution for infusion bottles
0501120L0AAABAB
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 100mg/50ml solution for infusion vials
0501120L0AABQBQ
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 100mg/5ml oral suspension
0501120L0AAAPAP
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 125mg/5ml oral suspension
0501120L0AAATAT
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 150mg/5ml oral suspension
0501120L0AABIBI
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 165mg/5ml oral suspension
0501120L0AABJBJ
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 170mg/5ml oral suspension
0501120L0AAAXAX
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 175mg/5ml oral suspension
0501120L0AABCBC
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 200mg/100ml infusion bags
0501120L0AABEBE
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 200mg/100ml solution for infusion bottles
0501120L0AAADAD
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 200mg/100ml solution for infusion vials
0501120L0AABRBR
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 20mg/5ml oral suspension
0501120L0AABKBK
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
|
Ciprofloxacin 375mg/5ml oral suspension
0501120L0AABBBB
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.